GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Goodwill-to-Asset

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Goodwill-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Clinuvel Pharmaceuticals's Goodwill for the quarter that ended in Dec. 2023 was $0.00 Mil. Clinuvel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $141.69 Mil. Therefore, Clinuvel Pharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 was 0.00.


Clinuvel Pharmaceuticals Goodwill-to-Asset Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Goodwill-to-Asset Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clinuvel Pharmaceuticals's Goodwill-to-Asset

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Goodwill-to-Asset falls into.



Clinuvel Pharmaceuticals Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Clinuvel Pharmaceuticals's Goodwill to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Goodwill to Asset (A: Jun. 2023 )=Goodwill/Total Assets
=0.128/130.009
=0.00

Clinuvel Pharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill to Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/141.687
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Clinuvel Pharmaceuticals Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022

CLINUVEL progresses innovative DNA Repair Program

By Marketwired Marketwired 09-10-2020

PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

By Marketwired Marketwired 07-13-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 07-09-2022

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023